

RECEIVED  
CENTRAL FAX CENTERFACSIMILE TRANSMISSION

AUG 18 2005

The information contained in this transmission is privileged and confidential. It is intended only for the use of the individual or entity named below. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited.

If you have received this communication in error, please notify Allergan immediately by telephone and return the original message to us at the below-indicated address via regular U.S. mail. Thank you.

**FROM:** Robert J. Baran  
2525 Dupont Drive  
Irvine, California 92612

**TO:** Examiner Golam M. Shameem  
U.S. Patent & Trademark Office

Phone No.: 714-246-4669

Facsimile No.: 714-246-4249

Facsimile No.: 571-273-8300

\*Number of pages (including this cover page): 18

Please acknowledge receipt of all pages indicated above  
by faxing this page back to Allergan, Inc. at the  
facsimile number provided above

In re: Andrews et al

Docket No. 17465DIV(AP)

Serial No.: 10/783,325; Filed 20 February 2004

Customer No.: 51957

Conf. No.: 6873

Title: 3-(ARYLAMINO)METHYLENE-1,3-DIHYDRO-2H-INDOL-2-ONES AS  
KINASE INHIBITORS

Date: August 18, 2005

Name or type of papers being transmitted:

Response to an Office Action dated 7 July 2005 and Terminal Disclaimer.

## CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below to the Central Fax Number 571-273-8300.

Date:

8/18/05

By:

Bonnie Ferguson